Cytotoxic Effects of Theranekron D6 on HepG2 Heaptocellular Carcinoma Cells
Abstract
Keywords
References
- [1] Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136(5) (2015) E359–86.
- [2] Torre L., Global cancer statistics, 2012, CA-CANCER J CLIN, 65(2) (2015) 87–108.
- [3] Park J.W., Chen M., Colombo M., Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study, LIVER INT, 35(9) (2015) 2155- 2166.
- [4] EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol., 56(4) (2012) 908–43.
- [5] Laursen L., A preventable cancer, Nature, 516(7529) (2014) S2– 3.
- [6] McGlynn KA, London W.T., “The global epidemiology of hepatocellular carcinoma: present and future”, Clin Liver Dis., 15(2) (2011) 223–x.
- [7] McGlynn K.A., Petrick J.L., London W.T., “Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability”, Clin Liver Dis., 19(2) (2015) 223– 38.
- [8] Sim H.W., Knox J., Hepatocellular carcinoma in the era of immunotherapy, Curr Probl Cancer, 42(1) (2018) 40– 48.
Details
Primary Language
English
Subjects
Biochemistry and Cell Biology (Other)
Journal Section
Research Article
Authors
Deniz Şumnulu
*
0009-0009-0693-3569
Türkiye
Publication Date
March 28, 2024
Submission Date
September 20, 2023
Acceptance Date
February 25, 2024
Published in Issue
Year 2024 Volume: 45 Number: 1
Cited By
Evaluation of Anticancer and Antimicrobial Potentials of Tarantula cubensis Venom (Theranekron® D6)
Erzincan Üniversitesi Fen Bilimleri Enstitüsü Dergisi
https://doi.org/10.18185/erzifbed.1463282